mao-b-in-16

MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 1.55 μM, suitable for research in central nervous system disorders such as Parkinson's disease [1].

MAO-B-IN-32 is an inhibitor of MAO-B (IC50= 16 nM) and can elevate dopamine levels in the brain by reducing MAO-B activity.

MAO-B-IN-46 (Compound 16) is a selective human MAO-B inhibitor with an IC50 of 26.8 nM, while showing weaker activity against hMAO-A (IC50: 7.2054 μM). This compound, also referred to as MAO-B-IN-46 (Compound 8), acts as an α-amylase inhibitor with an IC50 of 19.46 μM. It demonstrates certain neuroprotective properties and exhibits no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS radicals, with IC50 values of 17.86 and 17.71 μM, respectively. MAO-B-IN-46 is applicable in research on neurodegenerative diseases like Parkinson's, diabetes, and conditions related to oxidative stress.

LSD1-IN-16 (compound 4b) is a potent inhibitor of LSD1 that inhibits LSD1-CoREST, MAO-A, and MAO-B with IC50 values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 also induces cell growth arrest in prostate cancer LNCaP cells with an IC50 value of 15.2 μM [1].

PZ-1922 (Compound 16), able to cross the blood-brain barrier, is a dual antagonist for 5-HT6R and 5-HT3R with K i values of 17 nM and 0.45 nM, respectively. It also reversibly inhibits MAO-B with a pIC50 of 8.93. Moreover, PZ-1922 mitigates scopolamine (SCOP)-induced memory deficits in rats as observed in the novel object recognition (NOR) test and hinders Aβ-induced memory impairment in the T-maze test [1].